Selected research
Market Structure
Global Targeted Drugs for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Targeted Drugs for Multiple Sclerosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Targeted Drugs for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Targeted Drugs for Multiple Sclerosis include NOVARTIS, Roche, Biogen, Sanofi, Janssen and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Targeted Drugs for Multiple Sclerosis market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Targeted Drugs for Multiple Sclerosis and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Targeted Drugs for Multiple Sclerosis revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Targeted Drugs for Multiple Sclerosis market size, projected growth trends, production technologies, key applications, and end-use industries.
Targeted Drugs for Multiple Sclerosis Segment by Company
NOVARTIS
Roche
Biogen
Sanofi
Janssen
Bristol-Myers Squibb
Targeted Drugs for Multiple Sclerosis Segment by Type
Oral
Injection
Targeted Drugs for Multiple Sclerosis Segment by Application
Hospital
Clinic
Other
Targeted Drugs for Multiple Sclerosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Multiple Sclerosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Targeted Drugs for Multiple Sclerosis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted Drugs for Multiple Sclerosis industry.
Chapter 3: Detailed analysis of Targeted Drugs for Multiple Sclerosis companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Targeted Drugs for Multiple Sclerosisrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Clinic
- Other
Companies covered
- NOVARTIS
- Roche
- Biogen
- Sanofi
- Janssen
- Bristol-Myers Squibb
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Targeted Drugs for Multiple Sclerosis Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Oral
- 1.2.3 Injection
- 1.3 Market Analysis by Application
- 1.3.1 Global Targeted Drugs for Multiple Sclerosis Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Targeted Drugs for Multiple Sclerosis Growth Trends by Region
- 1.5.1 Global Targeted Drugs for Multiple Sclerosis Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Targeted Drugs for Multiple Sclerosis Market Size by Region (2021-2026)
- 1.5.3 Targeted Drugs for Multiple Sclerosis Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Targeted Drugs for Multiple Sclerosis Market Dynamics
- 2.1 Targeted Drugs for Multiple Sclerosis Industry Trends
- 2.2 Targeted Drugs for Multiple Sclerosis Industry Drivers
- 2.3 Targeted Drugs for Multiple Sclerosis Industry Opportunities and Challenges
- 2.4 Targeted Drugs for Multiple Sclerosis Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Targeted Drugs for Multiple Sclerosis Revenue by Company (2021-2026)
- 3.2 Global Targeted Drugs for Multiple Sclerosis Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Targeted Drugs for Multiple Sclerosis Key Company Head office and Area Served
- 3.4 Global Targeted Drugs for Multiple Sclerosis Company, Product Type & Application
- 3.5 Global Targeted Drugs for Multiple Sclerosis Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Targeted Drugs for Multiple Sclerosis Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Targeted Drugs for Multiple Sclerosis Players Market Share by Revenue in 2025
- 3.6.3 2025 Targeted Drugs for Multiple Sclerosis Tier 1, Tier 2, and Tier 3
4 Targeted Drugs for Multiple Sclerosis Market by Type
- 4.1 Global Targeted Drugs for Multiple Sclerosis Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Targeted Drugs for Multiple Sclerosis Market Size by Type (2021-2032)
- 4.3 Global Targeted Drugs for Multiple Sclerosis Market Size Share by Type (2021-2032)
5 Targeted Drugs for Multiple Sclerosis Market by Application
- 5.1 Global Targeted Drugs for Multiple Sclerosis Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Targeted Drugs for Multiple Sclerosis Market Size by Application (2021-2032)
- 5.3 Global Targeted Drugs for Multiple Sclerosis Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 NOVARTIS
- 6.1.1 NOVARTIS Company Information
- 6.1.2 NOVARTIS Business Overview
- 6.1.3 NOVARTIS Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 NOVARTIS Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.1.5 NOVARTIS Recent Developments
- 6.2 Roche
- 6.2.1 Roche Company Information
- 6.2.2 Roche Business Overview
- 6.2.3 Roche Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Roche Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.2.5 Roche Recent Developments
- 6.3 Biogen
- 6.3.1 Biogen Company Information
- 6.3.2 Biogen Business Overview
- 6.3.3 Biogen Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Biogen Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.3.5 Biogen Recent Developments
- 6.4 Sanofi
- 6.4.1 Sanofi Company Information
- 6.4.2 Sanofi Business Overview
- 6.4.3 Sanofi Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Sanofi Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.4.5 Sanofi Recent Developments
- 6.5 Janssen
- 6.5.1 Janssen Company Information
- 6.5.2 Janssen Business Overview
- 6.5.3 Janssen Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Janssen Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.5.5 Janssen Recent Developments
- 6.6 Bristol-Myers Squibb
- 6.6.1 Bristol-Myers Squibb Company Information
- 6.6.2 Bristol-Myers Squibb Business Overview
- 6.6.3 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Product Portfolio
- 6.6.5 Bristol-Myers Squibb Recent Developments
7 North America
- 7.1 North America Targeted Drugs for Multiple Sclerosis Market Size (2021-2032)
- 7.2 North America Targeted Drugs for Multiple Sclerosis Market Size by Type
- 7.2.1 North America Targeted Drugs for Multiple Sclerosis Market Size by Type (2021-2026)
- 7.2.2 North America Targeted Drugs for Multiple Sclerosis Market Size by Type (2027-2032)
- 7.2.3 North America Targeted Drugs for Multiple Sclerosis Market Share by Type (2021-2032)
- 7.3 North America Targeted Drugs for Multiple Sclerosis Market Size by Application
- 7.3.1 North America Targeted Drugs for Multiple Sclerosis Market Size by Application (2021-2026)
- 7.3.2 North America Targeted Drugs for Multiple Sclerosis Market Size by Application (2027-2032)
- 7.3.3 North America Targeted Drugs for Multiple Sclerosis Market Share by Application (2021-2032)
- 7.4 North America Targeted Drugs for Multiple Sclerosis Market Size by Country
- 7.4.1 North America Targeted Drugs for Multiple Sclerosis Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 7.4.3 North America Targeted Drugs for Multiple Sclerosis Market Size by Country (2027-2032)
- 7.4.4 North America Targeted Drugs for Multiple Sclerosis Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Targeted Drugs for Multiple Sclerosis Market Size (2021-2032)
- 8.2 Europe Targeted Drugs for Multiple Sclerosis Market Size by Type
- 8.2.1 Europe Targeted Drugs for Multiple Sclerosis Market Size by Type (2021-2026)
- 8.2.2 Europe Targeted Drugs for Multiple Sclerosis Market Size by Type (2027-2032)
- 8.2.3 Europe Targeted Drugs for Multiple Sclerosis Market Share by Type (2021-2032)
- 8.3 Europe Targeted Drugs for Multiple Sclerosis Market Size by Application
- 8.3.1 Europe Targeted Drugs for Multiple Sclerosis Market Size by Application (2021-2026)
- 8.3.2 Europe Targeted Drugs for Multiple Sclerosis Market Size by Application (2027-2032)
- 8.3.3 Europe Targeted Drugs for Multiple Sclerosis Market Share by Application (2021-2032)
- 8.4 Europe Targeted Drugs for Multiple Sclerosis Market Size by Country
- 8.4.1 Europe Targeted Drugs for Multiple Sclerosis Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 8.4.3 Europe Targeted Drugs for Multiple Sclerosis Market Size by Country (2027-2032)
- 8.4.4 Europe Targeted Drugs for Multiple Sclerosis Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Targeted Drugs for Multiple Sclerosis Market Size (2021-2032)
- 9.2 China Targeted Drugs for Multiple Sclerosis Market Size by Type
- 9.2.1 China Targeted Drugs for Multiple Sclerosis Market Size by Type (2021-2026)
- 9.2.2 China Targeted Drugs for Multiple Sclerosis Market Size by Type (2027-2032)
- 9.2.3 China Targeted Drugs for Multiple Sclerosis Market Share by Type (2021-2032)
- 9.3 China Targeted Drugs for Multiple Sclerosis Market Size by Application
- 9.3.1 China Targeted Drugs for Multiple Sclerosis Market Size by Application (2021-2026)
- 9.3.2 China Targeted Drugs for Multiple Sclerosis Market Size by Application (2027-2032)
- 9.3.3 China Targeted Drugs for Multiple Sclerosis Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Targeted Drugs for Multiple Sclerosis Market Size (2021-2032)
- 10.2 Asia Targeted Drugs for Multiple Sclerosis Market Size by Type
- 10.2.1 Asia Targeted Drugs for Multiple Sclerosis Market Size by Type (2021-2026)
- 10.2.2 Asia Targeted Drugs for Multiple Sclerosis Market Size by Type (2027-2032)
- 10.2.3 Asia Targeted Drugs for Multiple Sclerosis Market Share by Type (2021-2032)
- 10.3 Asia Targeted Drugs for Multiple Sclerosis Market Size by Application
- 10.3.1 Asia Targeted Drugs for Multiple Sclerosis Market Size by Application (2021-2026)
- 10.3.2 Asia Targeted Drugs for Multiple Sclerosis Market Size by Application (2027-2032)
- 10.3.3 Asia Targeted Drugs for Multiple Sclerosis Market Share by Application (2021-2032)
- 10.4 Asia Targeted Drugs for Multiple Sclerosis Market Size by Country
- 10.4.1 Asia Targeted Drugs for Multiple Sclerosis Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 10.4.3 Asia Targeted Drugs for Multiple Sclerosis Market Size by Country (2027-2032)
- 10.4.4 Asia Targeted Drugs for Multiple Sclerosis Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Type
- 11.2.1 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Application
- 11.3.1 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Country
- 11.4.1 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Targeted Drugs for Multiple Sclerosis Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst